Actively Recruiting
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
Led by Shanghai Chest Hospital · Updated on 2019-10-22
176
Participants Needed
6
Research Sites
430 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The ad-ESD trial is phase III randomized trial to compare adjuvant esophagectomy and chemoradiation for patients with clinical stage N0 and pathological stage T1b squamous cell carcinoma (after endoscopic submucosal dissection).
CONDITIONS
Official Title
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biopsy-proven esophageal squamous cell cancer
- Clinical N0 stage confirmed by imaging
- Pathological T1b stage confirmed by endoscopic submucosal dissection
- Age between 18 and 75 years
- Tumor located in the thoracic esophagus
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Signed written informed consent
You will not qualify if you...
- Previous treatment before endoscopic submucosal resection
- Unable to receive any treatment component
- Prior treatment for another primary tumor
- Presence of distant metastasis
- Tumor circumference involving more than three-quarters of the esophageal lumen
- Main tumor size larger than 5 cm by endoscopy
- Unable to understand the informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, JX 791
Active, Not Recruiting
2
Changhai Hospital, The Second Military Medical University
Shanghai, China, SH 21
Active, Not Recruiting
3
Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine
Shanghai, China, SH 21
Active, Not Recruiting
4
Shanghai Chest Hospital, Shanghai Jiao Tong University
Shanghai, China, SH 21
Actively Recruiting
5
Zhongshan Hospital, Fudan University
Shanghai, China, SH 21
Active, Not Recruiting
6
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Active, Not Recruiting
Research Team
Z
Zhigang Li, MD
CONTACT
X
Xiaobin Zhang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here